Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Tenax Therapeutics stock price, quote, forecast and news

TENX
US88032L2097
A2JEYS

Price

3.49
Today +/-
+0.04
Today %
+1.15 %
P

Tenax Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Tenax Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Tenax Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Tenax Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Tenax Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Tenax Therapeutics Stock Price History

DateTenax Therapeutics Price
9/27/20243.49 undefined
9/26/20243.45 undefined
9/25/20243.50 undefined
9/24/20243.41 undefined
9/23/20243.57 undefined
9/20/20243.57 undefined
9/19/20243.62 undefined
9/18/20243.61 undefined
9/17/20243.77 undefined
9/16/20243.78 undefined
9/13/20243.81 undefined
9/12/20243.69 undefined
9/11/20243.68 undefined
9/10/20243.74 undefined
9/9/20243.67 undefined
9/6/20243.68 undefined
9/5/20243.89 undefined
9/4/20243.82 undefined
9/3/20243.86 undefined

Tenax Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Tenax Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Tenax Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Tenax Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Tenax Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Tenax Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Tenax Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Tenax Therapeutics’s growth potential.

Tenax Therapeutics Revenue, EBIT and net profit per share

DateTenax Therapeutics RevenueTenax Therapeutics EBITTenax Therapeutics Net Income
2029e345.92 M undefined0 undefined104.14 M undefined
2028e255.6 M undefined239.02 M undefined77.74 M undefined
2027e143.18 M undefined123.47 M undefined52.35 M undefined
2026e0 undefined-16.98 M undefined-6.19 M undefined
2025e0 undefined-19.18 M undefined-8.31 M undefined
2024e0 undefined-17 M undefined-23.23 M undefined
20230 undefined-8.23 M undefined-7.71 M undefined
20220 undefined-11.05 M undefined-11.05 M undefined
20210 undefined-32.73 M undefined-32.98 M undefined
20200 undefined-9.87 M undefined-9.85 M undefined
20190 undefined-8.56 M undefined-8.39 M undefined
20180 undefined-6.89 M undefined-14.14 M undefined
20170 undefined-9.21 M undefined-8.84 M undefined
20160 undefined-19.39 M undefined-43.92 M undefined
20150 undefined-10.43 M undefined-10.07 M undefined
201449,300 undefined-13.78 M undefined-14.08 M undefined
2013288,700 undefined-16.61 M undefined-25.35 M undefined
201292,700 undefined-4.94 M undefined-10.37 M undefined
2011100,500 undefined-8.19 M undefined-15.71 M undefined
2010322,400 undefined-10.26 M undefined-10.45 M undefined
200947,400 undefined-10.2 M undefined-10.51 M undefined
20080 undefined-8.6 M undefined-33.22 M undefined
20070 undefined-2.93 M undefined-6.72 M undefined
20060 undefined-1.77 M undefined-3.33 M undefined
20050 undefined-2.48 M undefined-4.07 M undefined
20040 undefined-2.68 M undefined-2.67 M undefined

Tenax Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (k)DOCUMENTS
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000000000000000000000000000000143255345
----------------------------------78.3235.29
------------------------------------
000000000000000000000000000000000000
-1-2-1-100-2-3-2-2-2-2-1-2-8-10-10-8-4-16-13-10-19-9-6-8-9-32-11-8-17-19-161232390
---------------------------------86.0193.73-
-1-2-1-100-1-3-2-2-2-4-3-6-33-10-10-15-10-25-14-10-43-8-14-8-9-32-11-7-23-8-65277104
-100.00-50.00----200.00-33.33--100.00-25.00100.00450.00-69.70-50.00-33.33150.00-44.00-28.57330.00-81.4075.00-42.8612.50255.56-65.63-36.36228.57-65.22-25.00-966.6748.0835.06
0000000000000000000.10.30.90.90.90.913.94.612.918.4248.5000000
------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Tenax Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Tenax Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (k)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                         
0.080.050.740.195.474.252.440.180.30.5900.024.882.560.630.951.880.7858.3217.1320.1913.287.7312.865.46.715.582.129.79
00000000000003272139134453676497350000000
00000000000000003696300000000000
00000000000000535257839917729000000000
0.030.020.020.060.070.080.090.070.120.080.151.470.070.160.950.280.620.420.40.280.320.280.290.460.780.080.111.091.89
0.110.070.760.255.544.332.530.250.420.670.151.484.952.752.191.632.631.8458.9717.5120.5613.638.0613.326.186.85.693.2111.68
202137846231244486426408385299194178211384443294205124503619109176652951870
000000000000000000030.9818.028.591.81000000
00000000000000000000000000000
0.090.110.140.220.230.230.260.240.220.210.160.150.130.650.910.70.870.9323222200000000
00000000000000000011.2711.2711.2700000000
0000000000005.30.20.050.150.340.210.071.111.111.110.010.010.010.010.010.010
0.290.250.230.280.260.480.750.660.630.60.460.345.61.061.351.291.511.3434.4665.452.439.711.830.020.180.070.30.20
0.390.320.990.535.84.813.280.911.051.260.611.8210.563.83.532.924.143.1893.4382.9172.9923.349.8913.346.376.875.993.4111.68
                                                         
0.310.430.510.550.810.850.890.891.141.261.371.41.460.0200000000000000.010
5.477.589.419.7313.8216.5518.6818.7120.7123.2826.5329.646.0374.0483.5988.19107.28115.27219.47221.07221.29221.82222.4239.57239.94250.64282.74291.03305.35
-6.38-8.29-9.57-10.4-11.31-12.99-16.47-18.7-20.95-23.62-27.69-31.02-37.74-70.96-81.47-91.92-107.63-117.04-136.59-150.67-160.74-204.66-213.5-227.8-236.17-246.02-278.49-289.54-297.25
0000.022.540.0900-0.140.03-0.02000000000.03-0.13-0.02-0.02000000
00000000000000000000000000000
-0.6-0.280.35-0.095.854.53.10.90.750.950.19-0.029.753.12.13-3.73-0.35-1.7882.8970.4360.4217.148.8811.773.774.634.241.498.1
0.280.320.340.310.210.090.040.010.240.270.150.480.170.20.50.890.540.980.411.180.970.730.610.751.660.760.860.452.07
0.430.190.120.10.090.080.0300.060.040.080.10.050.240.841.251.270.690.732.663.115.250.360.820.871.240.70.781.01
000000000000000000.191.080.570.520.230.03000000
0.250.080.020.080000000.021.150.040.040.0601.2500000000000.620.5
1817601014517710600017612500043635834710000000120000
0.980.60.530.580.350.340.180.010.290.310.431.850.270.481.42.183.131.912.574.524.66.21.011.572.532.121.561.853.59
0.0200.10.05000000000.540.2304.461.362.9900000000.12000
0000000000000000007.967.967.9600000000
00000000000000000551100000600184640
0.0200.10.05000000000.540.2304.461.363.057.977.967.960000.060.120.180.060
0.990.60.640.630.350.340.180.010.290.310.431.850.810.71.46.654.494.9610.5412.4812.566.21.011.572.592.241.751.913.59
0.40.320.990.536.24.843.280.911.051.260.611.8210.563.813.532.924.143.1893.4382.9172.9923.349.8913.346.366.875.993.411.68
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Tenax Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Tenax Therapeutics's financial health and stability.

Assets

Tenax Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Tenax Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Tenax Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Tenax Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199419951996199719981999200020012002200320042005200620072008200920102011201220132014null20152016201720182019202020212022
-1-2-1-100-1-3-2-2-2-4-3-6-33-10-10-15-9-19-14-14-10-43-8-14-8-9-32-11
000000000000000000000000000000
00000000000000000000000-7000000
0000000000011324016401101-30000-1
00100001000001410009220340800220
000000000000000000000000000000
000000000000000000000000000000
-1-10000-1-1-2-1-1-2-1-2-4-8-8-8-4-9-9-9-8-15-12-5-7-9-10-12
000000000000000000000000000000
00000000000000000000-40-40422370000
00000000000000000000-40-40422370000
000000000000000000000000000000
000000000001170040400000000000
100106000220002748066066000801090
100106000221172799366066000801098
000000000000000000000000000007
000000000000000000000000000000
000005-1-1-200004-2-100-157-50-50-46-810-710-3
-1.78-1.24-0.91-0.63-0.88-0.94-1.62-1.9-2.12-1.79-2.03-2.18-1.16-2.3-4.33-8.9-8.62-8.53-5.05-9.4-9.860-8.97-15.87-12.14-5.51-7.56-9.27-10.87-12.01
000000000000000000000000000000

Tenax Therapeutics stock margins

The Tenax Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Tenax Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Tenax Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Tenax Therapeutics's sales revenue. A higher gross margin percentage indicates that the Tenax Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Tenax Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Tenax Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Tenax Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Tenax Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Tenax Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Tenax Therapeutics Margin History

Tenax Therapeutics Gross marginTenax Therapeutics Profit marginTenax Therapeutics EBIT marginTenax Therapeutics Profit margin
2029e100 %0 %30.1 %
2028e100 %93.51 %30.41 %
2027e100 %86.23 %36.56 %
2026e100 %0 %0 %
2025e100 %0 %0 %
2024e100 %0 %0 %
2023100 %0 %0 %
2022100 %0 %0 %
2021100 %0 %0 %
2020100 %0 %0 %
2019100 %0 %0 %
2018100 %0 %0 %
2017100 %0 %0 %
2016100 %0 %0 %
2015100 %0 %0 %
2014100 %-27,954.97 %-28,563.49 %
201355.04 %-5,753.76 %-8,779.08 %
201253.51 %-5,330.1 %-11,190.83 %
201149.05 %-8,149.95 %-15,634.23 %
201032.01 %-3,182.6 %-3,240.79 %
200917.72 %-21,522.15 %-22,167.51 %
2008100 %0 %0 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %0 %0 %
2004100 %0 %0 %

Tenax Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Tenax Therapeutics earnings per share therefore indicates how much revenue Tenax Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Tenax Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Tenax Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Tenax Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Tenax Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Tenax Therapeutics Revenue, EBIT and net profit per share

DateTenax Therapeutics Sales per ShareTenax Therapeutics EBIT per shareTenax Therapeutics Earnings per Share
2029e101.44 undefined0 undefined30.54 undefined
2028e74.96 undefined0 undefined22.8 undefined
2027e41.99 undefined0 undefined15.35 undefined
2026e0 undefined0 undefined-1.82 undefined
2025e0 undefined0 undefined-2.44 undefined
2024e0 undefined0 undefined-6.81 undefined
20230 undefined-33.13 undefined-31.03 undefined
20220 undefined-600.68 undefined-600.43 undefined
20210 undefined-2,537.07 undefined-2,556.9 undefined
20200 undefined-2,145.2 undefined-2,141.61 undefined
20190 undefined-2,193.67 undefined-2,152.41 undefined
20180 undefined-6,893.3 undefined-14,144.1 undefined
20170 undefined-10,228.78 undefined-9,821.89 undefined
20160 undefined-21,539.56 undefined-48,804.34 undefined
20150 undefined-11,583.89 undefined-11,186.67 undefined
201454.78 undefined-15,313.11 undefined-15,646.45 undefined
2013962.33 undefined-55,370.33 undefined-84,483.99 undefined
2012927 undefined-49,410 undefined-103,739.01 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined

Tenax Therapeutics business model

Tenax Therapeutics Inc. is a biopharmaceutical company based in Morrisville, North Carolina. It specializes in the development of therapeutics for cardiovascular and pulmonary diseases. The company was founded in 1967 by a group of physicians and scientists. Formerly known as Oxygen Biotherapeutics, it was rebranded as Tenax Therapeutics in 2014. Tenax Therapeutics' business model is focused on the development, manufacturing, and marketing of products for rare diseases. The company aims to develop innovative therapies for severe and life-threatening diseases where there is a high demand for novel treatment options. The focus of Tenax Therapeutics is on cardiovascular and respiratory diseases. The company specializes in the development of medications for the treatment of severe or life-threatening conditions such as cardiogenic shock, pulmonary hypertension, and pulmonary embolism. Over the years, Tenax Therapeutics has established several divisions to streamline its research and development activities. One of the key divisions is clinical research, where the company conducts clinical trials to test the efficacy and safety of its products and obtain regulatory approval. Another pillar of the company is product development, where Tenax Therapeutics develops new compounds and medications to specifically target conditions like cardiogenic shock. Given the high demand for new therapies for rare diseases, the company adopts a highly focused approach and concentrates on developing products for specific indications. Tenax Therapeutics' extensive product portfolio includes various medications and therapeutics that can be used to treat cardiovascular and pulmonary diseases. One important representative in this area is Levosimendan, a vasodilator and inotropic medication used in patients with cardiogenic shock, as well as heart failure and other cardiovascular conditions. Another product in Tenax Therapeutics' portfolio is the active substance ANX-188. This medication is used for the treatment of patients with severe cardiogenic shock and has already been tested in clinical trials. Overall, Tenax Therapeutics aims to develop innovative and effective therapies for rare diseases of the cardiovascular and pulmonary systems. The company strives to address the medical need in this field and ensure high patient satisfaction. Tenax Therapeutics is one of the most popular companies on Eulerpool.com.

Tenax Therapeutics SWOT Analysis

Strengths

Tenax Therapeutics Inc possesses several strengths that contribute to its competitive advantage:

  • Strong Market Position: Tenax Therapeutics Inc holds a favorable position within the pharmaceutical industry, allowing it to target a niche market segment.
  • Unique Product Portfolio: The company offers innovative and proprietary therapeutic solutions, differentiating itself from competitors.
  • Robust Research and Development: Tenax Therapeutics Inc invests significantly in R&D to constantly develop new products and improve existing ones, ensuring a sustainable pipeline of offerings.
  • Skilled Workforce: The company employs a team of highly skilled professionals with expertise in various areas of the pharmaceutical industry.

Weaknesses

Despite its strengths, Tenax Therapeutics Inc also faces certain weaknesses that could hinder its growth:

  • Limited Financial Resources: The company may face challenges in financing its R&D activities and expansion plans, which could restrict its growth potential.
  • Dependence on Key Personnel: Tenax Therapeutics Inc heavily relies on the expertise and knowledge of key personnel, posing a risk if they were to leave the company.
  • Product Dependence: The success of the company heavily relies on the performance and market acceptance of its existing and future products, leaving it vulnerable to market dynamics.

Opportunities

Tenax Therapeutics Inc can leverage the following opportunities to further enhance its growth prospects:

  • Expanding Market Demand: The growing demand for innovative pharmaceutical solutions provides an opportunity for Tenax Therapeutics Inc to increase its market share.
  • Strategic Partnerships: Collaborating with leading pharmaceutical companies or research institutions can enhance the company's access to resources, expertise, and potential distribution channels.
  • Market Expansion: Tenax Therapeutics Inc can explore geographic expansion to new markets that have a high demand for its products.

Threats

Tenax Therapeutics Inc faces the following threats that may impact its growth and profitability:

  • Intense Competition: The pharmaceutical industry is highly competitive, with numerous established players and new entrants, which may pose challenges for Tenax Therapeutics Inc to differentiate itself.
  • Regulatory Constraints: Compliance with regulations and obtaining necessary approvals can be time-consuming and expensive, impacting the speed of product development and market entry.
  • Technological Advancements: Rapid technological advancements in the pharmaceutical sector may render existing products or treatments obsolete, requiring Tenax Therapeutics Inc to continuously innovate and adapt.

Tenax Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Tenax Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Tenax Therapeutics shares outstanding

The number of shares was Tenax Therapeutics in 2023 — This indicates how many shares 248,500 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Tenax Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Tenax Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Tenax Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Tenax Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Tenax Therapeutics Stock splits

In Tenax Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Tenax Therapeutics.

Tenax Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-2.02 -1.83  (9.62 %)2024 Q2
3/31/2024-2.45 -3.12  (-27.45 %)2024 Q1
12/31/2023-8.31 -12.98  (-56.24 %)2023 Q4
9/30/2023-7.34 -6.4  (12.85 %)2023 Q3
6/30/2023-8.16 -4  (50.98 %)2023 Q2
3/31/2023-30.19 -12  (60.25 %)2023 Q1
12/31/2022-186.05 -138.4  (25.61 %)2022 Q4
9/30/2022-2.14 -2.2  (-2.71 %)2022 Q3
6/30/2022-1.84 -2.2  (-19.83 %)2022 Q2
12/31/2021-3.26 -0.8  (75.49 %)2021 Q4
1
2
3
4

Tenax Therapeutics list of shareholders

%
Name
Stocks
Change
Date
1.75953 % Heights Capital Management, Inc.60,00060,0002/12/2024
0.12469 % Renaissance Technologies LLC4,2524,25212/31/2023
0.09094 % Armistice Capital LLC3,1012,8851/30/2024
0.07786 % Rich (Stuart)2,65503/20/2024
0.07000 % Gofen and Glossberg, L.L.C._NLE2,387012/31/2022
0.07000 % Corient Private Wealth LLC2,387-612/31/2023
0.06821 % The Vanguard Group, Inc.2,326012/31/2023
0.06669 % Doogan (Declan)2,27403/20/2024
0.05428 % Geode Capital Management, L.L.C.1,85136412/31/2023
0.05220 % Two Sigma Investments, LP1,78056712/31/2023
1
2
3
4
...
5

Tenax Therapeutics Executives and Management Board

Mr. Christopher Giordano49
Tenax Therapeutics President, Chief Executive Officer, Director (since 2021)
Compensation 667,332
Dr. Stuart Rich73
Tenax Therapeutics Chief Medical Officer, Director (since 2021)
Compensation 468,144
Mr. Gerald Proehl64
Tenax Therapeutics Independent Chairman of the Board
Compensation 81,107
Ms. Robyn Hunter61
Tenax Therapeutics Independent Director
Compensation 68,259
Dr. June Almenoff66
Tenax Therapeutics Independent Director
Compensation 62,107
1
2

Tenax Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Orion B Stock
Orion B
SupplierCustomer0,080,610,44-0,42-0,46-0,39
1

Most common questions regarding Tenax Therapeutics

What values and corporate philosophy does Tenax Therapeutics represent?

Tenax Therapeutics Inc is dedicated to upholding core values and a strong corporate philosophy. They prioritize innovation, patient care, and scientific excellence in the field of biopharmaceuticals. The company aims to develop groundbreaking therapies to address crucial unmet needs within the healthcare industry. Tenax Therapeutics Inc values transparency, integrity, and collaboration, fostering relationships with key stakeholders and industry experts. By implementing cutting-edge research and development strategies, the company strives to bring novel treatment options to patients and improve their quality of life. Tenax Therapeutics Inc is committed to making a positive impact on the healthcare landscape and enhancing the overall well-being of their patients.

In which countries and regions is Tenax Therapeutics primarily present?

Tenax Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Tenax Therapeutics achieved?

Tenax Therapeutics Inc has achieved several significant milestones in its trajectory. One notable accomplishment is the successful completion of a Phase 3 clinical trial for their lead product candidate, Levosimendan. The trial demonstrated positive results in treating patients with pulmonary hypertension associated with heart failure. Additionally, Tenax Therapeutics Inc has secured FDA fast track designation for Levosimendan, recognizing its potential to address an unmet medical need. These milestones signify Tenax Therapeutics Inc's commitment to advancing innovative solutions in cardiovascular and pulmonary diseases, solidifying their position as a key player in the industry.

What is the history and background of the company Tenax Therapeutics?

Tenax Therapeutics Inc. is a pharmaceutical company with a rich history and background. Founded in 1967, Tenax has been dedicated to developing innovative therapies to address unmet medical needs. With headquarters in Morrisville, North Carolina, the company focuses on the discovery and commercialization of small molecule compounds for the treatment of cardiovascular diseases and other related conditions. Tenax has built a strong reputation for its cutting-edge research and commitment to patient health. Leveraging its expertise in drug formulation and clinical development, Tenax Therapeutics Inc. continues to strive towards improving the lives of patients worldwide.

Who are the main competitors of Tenax Therapeutics in the market?

Some of the main competitors of Tenax Therapeutics Inc in the market include companies like Athersys, Inc., BioCardia, Inc., and CryoLife, Inc. These companies also operate in the biotechnology or pharmaceutical industries and compete with Tenax Therapeutics Inc to develop innovative therapies and treatments.

In which industries is Tenax Therapeutics primarily active?

Tenax Therapeutics Inc primarily operates in the healthcare and pharmaceutical industries.

What is the business model of Tenax Therapeutics?

The business model of Tenax Therapeutics Inc is focused on developing and commercializing pharmaceutical products for critical care patients. The company primarily focuses on addressing acute-care conditions with limited therapeutic options. Tenax Therapeutics Inc aims to provide innovative and effective solutions for patients in need of urgent medical intervention. With a strong emphasis on research and development, the company strives to bring novel therapies to market that can improve the lives of individuals facing life-threatening conditions. Tenax Therapeutics Inc is committed to advancing the field of critical care medicine through its dedicated efforts and expertise.

What is the P/E ratio of Tenax Therapeutics 2024?

The Tenax Therapeutics P/E ratio is -0.04.

What is the P/S ratio of Tenax Therapeutics 2024?

The Tenax Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Tenax Therapeutics?

The AlleAktien quality score for Tenax Therapeutics is 2/10.

What is the revenue of Tenax Therapeutics 2024?

The revenue cannot currently be calculated for Tenax Therapeutics.

How high is the profit of Tenax Therapeutics 2024?

The expected Tenax Therapeutics profit is -23.23 M USD.

What is the business model of Tenax Therapeutics

Tenax Therapeutics Inc is a biopharmaceutical company specializing in the development and marketing of products for the treatment of heart and lung diseases. The company was founded in 1967 and is based in Morrisville, North Carolina. The main business of Tenax Therapeutics is the development of therapeutic products for the treatment of cardiovascular and pulmonary diseases. The company has two main products in the pipeline, both in clinical development: - Levosimendan: Levosimendan is an intravenously administered medication used for the treatment of patients with acute heart failure. The medication has already been approved in Europe and other countries and is currently being tested in a Phase 3 study in the United States. - Brensocatib: Brensocatib is an oral medication developed for the treatment of patients with chronic obstructive pulmonary disease (COPD). The medication shows promising results in clinical development and is expected to be approved in the coming years. Tenax Therapeutics also has a subsidiary called LifeAgain Insurance Solutions, specializing in the marketing of life insurance. However, this division of the company is not the core business and contributes only a small part to the revenue. The business model of Tenax Therapeutics is based on the development and marketing of innovative and successful medications for the treatment of cardiovascular and pulmonary diseases. The company works closely with academic research institutions and suppliers to accelerate the development of new products and advance scientific progress in this field. Tenax Therapeutics aims to sell and distribute its products worldwide to increase its revenue and expand its market presence. The company also intends to build long-term partnerships with other companies and organizations in the healthcare industry to expand its product pipeline and create new opportunities for research and development in the field of cardiovascular and pulmonary diseases. In summary, Tenax Therapeutics Inc is a leading company in the research and development of medications for the treatment of cardiovascular and pulmonary diseases. The company aims to sell its products worldwide and build long-term partnerships with other companies and organizations in the healthcare industry to expand its product pipeline and advance research in the field of cardiovascular and pulmonary diseases.

What is the Tenax Therapeutics dividend?

Tenax Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Tenax Therapeutics pay dividends?

The dividend cannot currently be calculated for Tenax Therapeutics or the company does not pay out a dividend.

What is the Tenax Therapeutics ISIN?

The ISIN of Tenax Therapeutics is US88032L2097.

What is the Tenax Therapeutics WKN?

The WKN of Tenax Therapeutics is A2JEYS.

What is the Tenax Therapeutics ticker?

The ticker of Tenax Therapeutics is TENX.

How much dividend does Tenax Therapeutics pay?

Over the past 12 months, Tenax Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Tenax Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Tenax Therapeutics?

The current dividend yield of Tenax Therapeutics is .

When does Tenax Therapeutics pay dividends?

Tenax Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Tenax Therapeutics?

Tenax Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Tenax Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Tenax Therapeutics located?

Tenax Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tenax Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tenax Therapeutics from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Tenax Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Tenax Therapeutics in the year 2023?

In the year 2023, Tenax Therapeutics distributed 0 USD as dividends.

In which currency does Tenax Therapeutics pay out the dividend?

The dividends of Tenax Therapeutics are distributed in USD.

All fundamentals about Tenax Therapeutics

Our stock analysis for Tenax Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tenax Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.